News | March 28, 2026
Novartis acquires Excellergy to bolster allergy portfolio
The move leverages Novartis’ deep expertise in IgE biology and long-standing presence in allergic disease treatments
The move leverages Novartis’ deep expertise in IgE biology and long-standing presence in allergic disease treatments
TERN-701, a next-generation therapy targeting chronic myeloid leukemia (CML), a form of blood cancer that still presents treatment challenges despite decades of advances
At the center of the collapse is opposition from the Federal Trade Commission
The initial consideration for the transaction is US$ 12 million
Rivotril is the innovator/ reference brand of clonazepam and is widely prescribed for the management of neurological and psychiatric conditions
The expanded ownership is expected to improve access to Cialis for millions of men in Asia affected by ED and BPH
The endorsement follows overwhelming support for the share swap preceding the merger,
Remidex manufactures micronutrient premixes and nutraceuticals,
The acquisition of Biocare enhances Agilent’s pathology portfolio and reflects our strategy to drive long-term growth
Launches advanced bone density systems in India & Dubai
Subscribe To Our Newsletter & Stay Updated
